Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca Gardner(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital)

Blood

April 13, 2017

10.1182/blood-2017-02-769208

Cited by 1,130

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

|New England Journal of Medicine|2016|1.8k

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

|Clinical Cancer Research|2015|754

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

|Blood|2016|743

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

|Blood|2008|719

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

|Blood|2011|600